Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clinical stage biotechnology company Galapagos has achieved a milestone in collaboration with Janssen Pharmaceutica, by delivering a second pre-clinical compound.
Subscribe to our email newsletter
Galapagos earns a milestone payment of EUR4m from Janssen for achieving the milestone of identifying a second pre-clinical candidate.
According to the deal signed between the two companies in 2007, Janssen Pharmaceutica has option rights to obtain global, commercial licenses to certain internal programs of Galapagos.
Galapagos CEO Onno van de Stolpe said the company delivered a second candidate drug in the alliance with Janssen.
"Galapagos is progressing multiple programs successfully across different alliances and delivering promising candidate drugs," Onno van de Stolpe added.